Bioxyne subsidiary Breathe Life Sciences (BLS) has signed its first medicinal cannabis flower supply agreement in Costa Rica.
The deal was struck with Remidose LATAM, a Costa Rican subsidiary of Canadian firm Remidose Aerosols, which specialises in precision-dosed metered THC inhalers and transdermal topical gels.
The agreement expands on an existing December 2025 deal inked between the groups covering the supply of pastilles into Costa Rica and Panama.
Bioxyne said the arrangement, which will see the firm supply three Dr Watson-branded cannabis flower SKUs, marked the first international supply of medicinal cannabis flower into Costa Rica.
The first shipment was expected before June 30, with the initial invoice set to exceed $500,000.
Chief executive Sam Watson said the expanded agreement showed how quickly opportunities could evolve once a foothold was established in growing markets.
“We’ve moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we’re seeing on the ground,” he said.
“LATAM is still early in its development, but that’s exactly where we see the opportunity.
“Being the first to supply branded medicinal cannabis flower into Costa Rica positions us ahead of competing suppliers and gives us the platform to expand into other LATAM jurisdictions as those markets continue to open.”
Remidose managing director Michael Mayne added: “We are pleased to be making the first ever shipment of medicinal cannabis flower into Costa Rica and are delighted to be doing this with the Dr Watson-branded products.
“Early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market. This is an exciting time for both companies.”
Article by Cannabiz: https://www.cannabiz.com.au/bioxyne-lands-first-costa-rica-flower-supply-deal/